Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

Immunosuppressive therapy with rituximab in common variable immunodeficiency.

Pecoraro A, Crescenzi L, Galdiero MR, Marone G, Rivellese F, Rossi FW, de Paulis A, Genovese A, Spadaro G.

Clin Mol Allergy. 2019 May 6;17:9. doi: 10.1186/s12948-019-0113-3. eCollection 2019. Review.

2.

Superantigenic Activation of Human Cardiac Mast Cells.

Varricchi G, Loffredo S, Borriello F, Pecoraro A, Rivellese F, Genovese A, Spadaro G, Marone G.

Int J Mol Sci. 2019 Apr 12;20(8). pii: E1828. doi: 10.3390/ijms20081828.

3.

Double-blind, placebo-controlled, randomized trial on low-dose azithromycin prophylaxis in patients with primary antibody deficiencies.

Milito C, Pulvirenti F, Cinetto F, Lougaris V, Soresina A, Pecoraro A, Vultaggio A, Carrabba M, Lassandro G, Plebani A, Spadaro G, Matucci A, Fabio G, Dellepiane RM, Martire B, Agostini C, Abeni D, Tabolli S, Quinti I.

J Allergy Clin Immunol. 2019 Mar 22. pii: S0091-6749(19)30388-4. doi: 10.1016/j.jaci.2019.01.051. [Epub ahead of print]

4.

Health-Related Quality of Life in Patients with CVID Under Different Schedules of Immunoglobulin Administration: Prospective Multicenter Study.

Pulvirenti F, Cinetto F, Pecoraro A, Carrabba M, Crescenzi L, Neri R, Bonanni L, Fabio G, Agostini C, Spadaro G, Tabolli S, Farrugia A, Quinti I, Milito C.

J Clin Immunol. 2019 Feb;39(2):159-170. doi: 10.1007/s10875-019-0592-5. Epub 2019 Jan 15.

5.

Prostaglandin D2 receptor antagonists in allergic disorders: safety, efficacy, and future perspectives.

Marone G, Galdiero MR, Pecoraro A, Pucino V, Criscuolo G, Triassi M, Varricchi G.

Expert Opin Investig Drugs. 2019 Jan;28(1):73-84. doi: 10.1080/13543784.2019.1555237. Epub 2018 Dec 7. Review.

PMID:
30513028
6.

Gastric Cancer Is the Leading Cause of Death in Italian Adult Patients With Common Variable Immunodeficiency.

Pulvirenti F, Pecoraro A, Cinetto F, Milito C, Valente M, Santangeli E, Crescenzi L, Rizzo F, Tabolli S, Spadaro G, Agostini C, Quinti I.

Front Immunol. 2018 Nov 5;9:2546. doi: 10.3389/fimmu.2018.02546. eCollection 2018.

7.

Gastroduodenal Disorders in Patients with CVID Undergoing Immunoglobulin Therapy.

Varricchi G, Pecoraro A, Crescenzi L, Marone G, Travaglino A, D'Armiento FP, Genovese A, Spadaro G.

Curr Pharm Biotechnol. 2018;19(9):734-741. doi: 10.2174/1389201019666181010170630.

PMID:
30336770
8.

Validation of Calculated Globulin (CG) as a Screening Test for Antibody Deficiency in an Italian University Hospital.

Pecoraro A, Jolles S, Crescenzi L, Varricchi G, Marone G, Savoia M, Genovese A, Spadaro G.

Curr Pharm Biotechnol. 2018;19(9):728-733. doi: 10.2174/1389201019666180808163311.

PMID:
30091407
9.

Thymic Stromal Lymphopoietin Isoforms, Inflammatory Disorders, and Cancer.

Varricchi G, Pecoraro A, Marone G, Criscuolo G, Spadaro G, Genovese A, Marone G.

Front Immunol. 2018 Jul 13;9:1595. doi: 10.3389/fimmu.2018.01595. eCollection 2018. Review.

10.

Biweekly Hizentra® in Primary Immunodeficiency: a Multicenter, Observational Cohort Study (IBIS).

Vultaggio A, Azzari C, Ricci S, Martire B, Palladino V, Gallo V, Pecoraro A, Pignata C, Spadaro G, Graziani S, Moschese V, Trizzino A, Boggia GM, Matucci A.

J Clin Immunol. 2018 Jul;38(5):602-609. doi: 10.1007/s10875-018-0528-5. Epub 2018 Jun 28.

11.

Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective.

Varricchi G, Ameri P, Cadeddu C, Ghigo A, Madonna R, Marone G, Mercurio V, Monte I, Novo G, Parrella P, Pirozzi F, Pecoraro A, Spallarossa P, Zito C, Mercuro G, Pagliaro P, Tocchetti CG.

Front Physiol. 2018 Mar 7;9:167. doi: 10.3389/fphys.2018.00167. eCollection 2018. Review.

12.

Chronic Diarrhea in Common Variable Immunodeficiency: a Case Series and Review of the Literature.

Pecoraro A, Nappi L, Crescenzi L, D'Armiento FP, Genovese A, Spadaro G.

J Clin Immunol. 2018 Jan;38(1):67-76. doi: 10.1007/s10875-017-0461-z. Epub 2017 Nov 14.

PMID:
29138951
13.

Corrigendum to "Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia" [Int. Immunopharmacol. 44 (2017) 38-42].

Spadaro G, Vultaggio A, Bosi A, Reichert D, Janssen J, Lamacchia D, Nappi L, Pecoraro A, Milito C, Ferraro A, Matucci A, Bacchiarri F, Carrai V, Hibbeler A, Speckman E, Guarnieri C, Bongiovanni S, Quinti I.

Int Immunopharmacol. 2018 Apr;57:201. doi: 10.1016/j.intimp.2017.10.014. Epub 2017 Oct 28. No abstract available.

PMID:
29089244
14.

Immunoglobulin replacement therapy in primary and secondary antibody deficiency: The correct clinical approach.

Pecoraro A, Crescenzi L, Granata F, Genovese A, Spadaro G.

Int Immunopharmacol. 2017 Nov;52:136-142. doi: 10.1016/j.intimp.2017.09.005. Epub 2017 Oct 12. Review.

PMID:
28898770
15.

Total and High Molecular Weight Adiponectin Expression Is Decreased in Patients with Common Variable Immunodeficiency: Correlation with Ig Replacement Therapy.

Pecoraro A, Nigro E, Polito R, Monaco ML, Scudiero O, Mormile I, Cesoni Marcelli A, Capasso M, Habetswallner F, Genovese A, Daniele A, Spadaro G.

Front Immunol. 2017 Jul 31;8:895. doi: 10.3389/fimmu.2017.00895. eCollection 2017.

16.

Delay in diagnosis affects the clinical outcome in a cohort of cvid patients with marked reduction of iga serum levels.

Graziano V, Pecoraro A, Mormile I, Quaremba G, Genovese A, Buccelli C, Paternoster M, Spadaro G.

Clin Immunol. 2017 Jul;180:1-4. doi: 10.1016/j.clim.2017.03.011. Epub 2017 Mar 25.

PMID:
28347823
17.

Heart failure not responsive to standard immunosuppressive therapy is successfully treated with high dose intravenous immunoglobulin therapy in a patient with Eosinophilic Granulomatosis with Polyangiitis (EGPA).

Pecoraro A, Crescenzi L, Carucci L, Genovese A, Spadaro G.

Int Immunopharmacol. 2017 Apr;45:13-15. doi: 10.1016/j.intimp.2017.01.025. Epub 2017 Jan 31.

PMID:
28152445
18.

Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia.

Spadaro G, Vultaggio A, Alberto Bosi A, Reichert D, Janssen J, Lamacchia D, Nappi L, Pecoraro A, Milito C, Ferraro A, Matucci A, Bacchiarri F, Carrai V, Hibbeler A, Speckman E, Guarnieri C, Bongiovanni S, Quinti I.

Int Immunopharmacol. 2017 Mar;44:38-42. doi: 10.1016/j.intimp.2016.12.030. Epub 2017 Jan 7. Erratum in: Int Immunopharmacol. 2018 Apr;57:201.

PMID:
28073042
19.

Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.

Canessa C, Iacopelli J, Pecoraro A, Spadaro G, Matucci A, Milito C, Vultaggio A, Agostini C, Cinetto F, Danieli MG, Gambini S, Marasco C, Trizzino A, Vacca A, De Mattia D, Martire B, Plebani A, Di Gioacchino M, Gatta A, Finocchi A, Licciardi F, Martino S, De Carli M, Moschese V, Azzari C.

Int J Immunopathol Pharmacol. 2017 Mar;30(1):73-82. doi: 10.1177/0394632016681577. Epub 2016 Dec 7.

20.

Intravenous versus subcutaneous immunoglobulin replacement in secondary hypogammaglobulinemia.

Spadaro G, Pecoraro A, De Renzo A, Della Pepa R, Genovese A.

Clin Immunol. 2016 May;166-167:103-4. doi: 10.1016/j.clim.2016.04.001. Epub 2016 Apr 7.

PMID:
27063866

Supplemental Content

Loading ...
Support Center